诺泰生物
(688076)
| 流通市值：107.03亿 | | | 总市值：107.03亿 |
| 流通股本：2.20亿 | | | 总股本：2.20亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,252,252,784.74 | 831,498,746.79 | 355,815,137.72 | 1,033,548,079.03 |
| 营业收入 | 1,252,252,784.74 | 831,498,746.79 | 355,815,137.72 | 1,033,548,079.03 |
| 二、营业总成本 | 832,401,194.11 | 552,758,685.92 | 268,734,197.03 | 827,280,234.64 |
| 营业成本 | 384,214,016.79 | 271,763,389.66 | 116,478,624.19 | 403,395,372.22 |
| 税金及附加 | 7,171,997.74 | 4,062,312.08 | 705,184.14 | 7,201,629.17 |
| 销售费用 | 46,441,615.96 | 28,667,949.96 | 11,485,845.29 | 57,625,282.51 |
| 管理费用 | 205,971,512.31 | 130,667,954.41 | 70,571,854.29 | 222,579,291.53 |
| 研发费用 | 172,750,863.81 | 112,494,851.21 | 66,247,412.85 | 124,889,236.61 |
| 财务费用 | 15,851,187.5 | 5,102,228.6 | 3,245,276.27 | 11,589,422.6 |
| 其中:利息费用 | 23,090,156.75 | 13,884,208.1 | 6,347,691.06 | 16,085,329.99 |
| 其中:利息收入 | 5,553,161.61 | 3,148,670.73 | 1,262,960.83 | 6,207,703.28 |
| 加:公允价值变动收益 | -4,696,871.91 | -3,133,714.68 | - | 257,516.79 |
| 加:投资收益 | 97,288.38 | -463,054.67 | 173,464.72 | 2,903,701.2 |
| 资产处置收益 | -32,858.25 | - | - | 176,417.14 |
| 资产减值损失(新) | -16,863,144.47 | -10,140,579.59 | -6,142,181.86 | -28,892,606.29 |
| 信用减值损失(新) | -18,509,225.46 | -13,073,760.27 | -3,559,938.47 | -5,240,686.62 |
| 其他收益 | 9,582,615.46 | 6,981,052.34 | 3,267,875.41 | 14,193,608.3 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 389,429,394.38 | 258,910,004 | 80,820,160.49 | 189,665,794.91 |
| 加:营业外收入 | 981,200.39 | 385,275.21 | 69,733.2 | 554,638.78 |
| 减:营业外支出 | 5,171,273.64 | 2,332,626.47 | 439,183.07 | 17,093,559.71 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 385,239,321.13 | 256,962,652.74 | 80,450,710.62 | 173,126,873.98 |
| 减:所得税费用 | 34,542,851.04 | 25,197,489.05 | 15,885,785.67 | 7,674,212.02 |
| 六、净利润 | 350,696,470.09 | 231,765,163.69 | 64,564,924.95 | 165,452,661.96 |
| 持续经营净利润 | 350,696,470.09 | 231,765,163.69 | 64,564,924.95 | 165,452,661.96 |
| 归属于母公司股东的净利润 | 350,247,058.35 | 227,161,523.34 | 66,326,817.02 | 162,936,105.25 |
| 少数股东损益 | 449,411.74 | 4,603,640.35 | -1,761,892.07 | 2,516,556.71 |
| (一)基本每股收益 | 1.62 | 1.06 | 0.31 | 0.76 |
| (二)稀释每股收益 | 1.58 | 1.01 | 0.3 | 0.76 |
| 八、其他综合收益 | - | - | - | -24,617,700 |
| 归属于母公司股东的其他综合收益 | - | - | - | -24,617,700 |
| 九、综合收益总额 | 350,696,470.09 | 231,765,163.69 | 64,564,924.95 | 140,834,961.96 |
| 归属于母公司股东的综合收益总额 | 350,247,058.35 | 227,161,523.34 | 66,326,817.02 | 138,318,405.25 |
| 归属于少数股东的综合收益总额 | 449,411.74 | 4,603,640.35 | -1,761,892.07 | 2,516,556.71 |
| 公告日期 | 2024-10-23 | 2024-08-23 | 2024-04-23 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |